In Brief: Abbott's Ritonavir

Abbott's Ritonavir: FDA Antiviral Drugs Advisory Committee will meet Feb. 29 to consider Abbott's NDA for the protease inhibitor for treatment of HIV infection. On. Feb. 28, the committee will discuss data from AIDS Clinical Trial Group study 175 and other studies with Bristol-Myers Squibb's Videx, Glaxo Welcome's Retrovir and Roche's Hivid. The committee will meet jointly with FDA's Endocrinologic & Metabolic Drugs Advisory Committee on March 1 to discuss Serono's NDA for Serostim hgH for AIDS wasting syndrome. The three-day meeting will be held at the Holiday Inn in Gaithersburg, Md. starting at 8:30 a.m. on Feb. 28 & 29, and at 8 a.m. March 1...